Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies using its proprietary DELigase platform. The company focuses on E3 ligase modulation to create oral small molecule drugs for oncology and immunology, with lead programs including NX-2127 (BTK degrader for B-cell malignancies) and NX-5948 (BTK degrader for autoimmune diseases) in Phase 1/2 trials. Revenue primarily consists of collaboration payments from partnerships with Sanofi and Gilead, while the company remains pre-commercial with significant cash burn.
Nurix operates a dual-track model: (1) proprietary pipeline development where it retains full economics on lead programs like NX-2127 and NX-5948, targeting eventual commercialization or acquisition, and (2) platform partnerships where it licenses its DELigase discovery engine to pharma partners for upfront payments ($20-50M typical), research funding, development milestones (potentially $500M+ per program), and royalties on commercialized products. The company's competitive advantage lies in its proprietary library of E3 ligase binders and computational platform enabling rapid identification of degrader molecules. Current revenue is entirely non-product, creating high gross margins but requiring substantial capital until clinical validation or partnership expansion.
Clinical trial data readouts for NX-2127 (BTK degrader) and NX-5948 - efficacy, safety, and differentiation versus existing BTK inhibitors like Imbruvica and Calquence
New partnership announcements or expansion of existing Sanofi/Gilead collaborations - upfront payments, milestone structures, and validation of DELigase platform
Regulatory milestones including IND filings for new programs and Phase 2 trial initiations for lead assets
Cash runway updates and financing activities - equity raises, debt facilities, or non-dilutive funding that extend operational runway beyond current 18-24 month estimates
Competitive developments in protein degradation space - rival programs from Arvinas, C4 Therapeutics, Kymera, or large pharma internal efforts
Clinical trial failure risk - NX-2127 or NX-5948 could fail to demonstrate sufficient efficacy or acceptable safety versus existing BTK inhibitors, potentially eliminating 60-70% of current pipeline value and triggering significant stock decline
Protein degradation platform validation risk - technology remains relatively novel with limited approved precedents (only Imbruvica/Calquence as BTK inhibitors, no approved degraders), creating uncertainty around commercial viability and competitive differentiation
Regulatory pathway uncertainty for novel degrader mechanisms - FDA may require additional safety studies or longer development timelines given limited precedent, extending time-to-market and capital requirements
Intense competition in BTK degrader space from Arvinas (ARV-471 breast cancer focus but platform overlap), C4 Therapeutics, Kymera Therapeutics, and internal programs at Roche, Bristol Myers Squibb creating risk of faster-moving rivals reaching market first or demonstrating superior profiles
Existing BTK inhibitor franchise strength - Imbruvica, Calquence, Brukinsa generate $8B+ combined sales with established efficacy, creating high bar for degrader differentiation and potential physician reluctance to switch established therapies
Cash runway constraints - estimated 18-24 month runway at current $80-100M annual burn rate requires near-term financing, likely dilutive equity raise in 2026-2027 that could pressure stock if executed at unfavorable valuations
Partnership dependency risk - 70-80% of current revenue from two collaborations creates concentration risk; termination or restructuring of Sanofi or Gilead agreements would significantly impact financial flexibility and require accelerated capital raise
low - Clinical-stage biotech with no product revenue, insulated from consumer spending or GDP fluctuations. Development timelines driven by scientific milestones rather than economic conditions. However, partnership activity and M&A valuations can be affected during severe recessions when pharma companies reduce external investment. Collaboration revenue (~$100M TTM) provides modest stability but represents research funding rather than economically-sensitive product sales.
Rising interest rates create moderate headwinds through two channels: (1) higher discount rates compress NPV of distant cash flows from pipeline assets (2028+ commercialization), disproportionately impacting pre-revenue biotech valuations and contributing to sector multiple compression, and (2) increased opportunity cost makes cash-burning growth stocks less attractive versus risk-free alternatives, reducing investor appetite for speculative biotech. However, $350-400M cash position (estimated) generates modest interest income benefit. Rate sensitivity primarily manifests through valuation multiples rather than operational impact.
Minimal direct credit exposure given strong balance sheet with 7.02x current ratio and low 0.10 debt/equity ratio. Company not dependent on credit markets for operations. However, tighter credit conditions can indirectly impact through: (1) reduced pharma M&A activity affecting potential acquisition premium, (2) more expensive equity financing if capital raise needed to extend runway, and (3) partner financial health affecting collaboration payment timing. Widening high-yield spreads signal risk-off environment that typically pressures speculative biotech stocks regardless of individual credit quality.
growth - Attracts speculative biotech investors focused on clinical-stage pipeline optionality and platform technology upside. The 47.8% six-month return reflects momentum from positive clinical updates or partnership news, while -6.5% one-year return shows volatility typical of binary event-driven biotech. Not suitable for value or income investors given negative profitability, no dividends, and high cash burn. Investor base consists primarily of biotech-specialized funds, crossover healthcare investors, and retail traders seeking high-risk/high-reward clinical catalyst plays.
high - Clinical-stage biotech with binary trial outcomes creating 20-40% single-day moves on data releases. $1.4B market cap provides limited liquidity, amplifying volatility. Recent 22.3% three-month gain demonstrates momentum sensitivity. Stock highly correlated with biotech sector sentiment (XBI ETF) and risk appetite, with elevated beta estimated at 1.5-2.0x versus broader market. Volatility will remain elevated until commercial-stage revenue diversification (2028+ timeline).
